Multiple Myeloma | Specialty

Stem Cell Transplantation and Novel Therapy

August 13th 2019

Optimizing Therapy for Patients With Multiple Myeloma

August 13th 2019

Navigating Through Testicular Cancer Treatment

August 13th 2019

Relapsed Myeloma: With Great Options Comes Great Responsibility

August 9th 2019

Noopur Raje, MD, highlights the multitude of available and emerging options in relapsed myeloma, as well as the key factors for treatment selection in this heterogeneous population.

Dr. Chari on the Use of Frontline Daratumumab in Transplant-Eligible Patients With Myeloma

August 8th 2019

Ajai Chari, MD, associate professor, hematology and medical oncology, Mount Sinai Hospital, discusses the use of frontline daratumumab (Darzalex) in transplant-eligible patients with multiple myeloma.

Experts Discuss Highly Anticipated Study Results Across Tumor Types

August 5th 2019

OncLive interviewed experts at the State of the Science Summits in July 2019 on highly anticipated clinical trial results across tumor types.

Dr. Gasparetto on Key Trials in Relapsed/Refractory Multiple Myeloma

August 2nd 2019

Cristina Gasparetto, MD, an associate professor of medicine, Duke University Medical Center, and director, Multiple Myeloma Program at Duke Cancer Institute, discusses key trials in relapsed/refractory multiple myeloma.

Dr. Cowan on the Role of Venetoclax in Multiple Myeloma

August 1st 2019

Andrew J. Cowan, MD, an assistant professor of medicine at University of Washington and hematologist/oncologist at Seattle Cancer Care Alliance, discusses the role of venetoclax (Venclexta) in multiple myeloma.

QoL Comes Into Focus in Myeloma Amid Expanding Treatment Options

July 31st 2019

David Samuel Dicapua Siegel, MD, highlights key research in multiple myeloma and the renewed focus on improving quality of life.

Landgren Reflects on Recent Breakthroughs in Multiple Myeloma

July 30th 2019

C. Ola Landgren, MD, PhD, shares his expert insight on recent shifts in multiple myeloma management.

Dr. Chari on the E3A06 Trial in Smoldering Myeloma

July 29th 2019

Ajai Chari, MD, associate professor, hematology and medical oncology, Mount Sinai Hospital, discusses the phase III E3A06 study, which looked at the effects of lenalidomide in patients with smoldering myeloma.

Multiagent Regimens Progress Further in Frontline Myeloma

July 29th 2019

Kenneth C. Anderson, MD, discusses available and emerging frontline treatment regimens for patients with newly diagnosed multiple myeloma and evaluated the utility of minimal residual disease in the paradigm.

Elotuzumab Triplet Approaches EU Approval for Multiple Myeloma

July 29th 2019

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approving elotuzumab (Empliciti) for use in combination with pomalidomide (Pomalyst) and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide (Revlimid) and a proteasome inhibitor.

Quadruplet Regimens Show Promising Activity in Multiple Myeloma

July 26th 2019

Ajai Chari, MD, discusses current and emerging research in patients with transplant-eligible and -ineligible multiple myeloma as well as updates in smoldering multiple myeloma.

Novel CAR T-Cell Approaches Emerging in Multiple Myeloma

July 25th 2019

Deepu Madduri, MD, discusses ongoing trials examining CAR T-cell therapy in myeloma and the potential to use it in earlier lines of therapy.

Dr. Nadeem on Individualizing Therapy in Multiple Myeloma

July 25th 2019

Omar Nadeem, MD, a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, discusses individualizing therapy for patients with multiple myeloma.

Isatuximab Triplet Highly Active in Relapsed/Refractory Myeloma

July 24th 2019

Paul G. Richardson, MD, reviews the results of the phase III ICARIA-MM trial as well as preliminary data regarding melflufen in relapsed/refractory multiple myeloma.

Dr. Richardson Discusses New Directions in Multiple Myeloma

July 24th 2019

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, discusses new directions in multiple myeloma.

Dr. Raje Highlights Treatment Options for Relapsed Multiple Myeloma

July 18th 2019

Noopur S. Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, and professor of medicine, Harvard Medical School, highlights the different options available for patients with relapsed multiple myeloma.

Dr. Cowan on Patient Eligibility Criteria for Transplant in Multiple Myeloma

July 17th 2019

Andrew J. Cowan, MD, an assistant professor of medicine at University of Washington School of Medicine and hematologist/oncologist at Seattle Cancer Care Alliance, discusses patient eligibility criteria for transplant in multiple myeloma.